Cargando…

An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping

Optogenetic tools such as channelrhodopsin-2 (ChR2) enable the manipulation and mapping of neural circuits. However, ChR2 variants selectively transported down a neuron’s long-range axonal projections for precise presynaptic activation remain lacking. As a result, ChR2 activation is often contaminat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Shun, Nagase, Masashi, Yoshizawa, Tomohiko, Hagiwara, Akari, Isomura, Yoshikazu, Watabe, Ayako M., Ohtsuka, Toshihisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042110/
https://www.ncbi.nlm.nih.gov/pubmed/33846537
http://dx.doi.org/10.1038/s42003-021-01977-7
_version_ 1783678057626730496
author Hamada, Shun
Nagase, Masashi
Yoshizawa, Tomohiko
Hagiwara, Akari
Isomura, Yoshikazu
Watabe, Ayako M.
Ohtsuka, Toshihisa
author_facet Hamada, Shun
Nagase, Masashi
Yoshizawa, Tomohiko
Hagiwara, Akari
Isomura, Yoshikazu
Watabe, Ayako M.
Ohtsuka, Toshihisa
author_sort Hamada, Shun
collection PubMed
description Optogenetic tools such as channelrhodopsin-2 (ChR2) enable the manipulation and mapping of neural circuits. However, ChR2 variants selectively transported down a neuron’s long-range axonal projections for precise presynaptic activation remain lacking. As a result, ChR2 activation is often contaminated by the spurious activation of en passant fibers that compromise the accurate interpretation of functional effects. Here, we explored the engineering of a ChR2 variant specifically localized to presynaptic axon terminals. The metabotropic glutamate receptor 2 (mGluR2) C-terminal domain fused with a proteolytic motif and axon-targeting signal (mGluR2-PA tag) localized ChR2-YFP at axon terminals without disturbing normal transmission. mGluR2-PA-tagged ChR2 evoked transmitter release in distal projection areas enabling lower levels of photostimulation. Circuit connectivity mapping in vivo with the Spike Collision Test revealed that mGluR2-PA-tagged ChR2 is useful for identifying axonal projection with significant reduction in the polysynaptic excess noise. These results suggest that the mGluR2-PA tag helps actuate trafficking to the axon terminal, thereby providing abundant possibilities for optogenetic experiments.
format Online
Article
Text
id pubmed-8042110
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80421102021-04-28 An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping Hamada, Shun Nagase, Masashi Yoshizawa, Tomohiko Hagiwara, Akari Isomura, Yoshikazu Watabe, Ayako M. Ohtsuka, Toshihisa Commun Biol Article Optogenetic tools such as channelrhodopsin-2 (ChR2) enable the manipulation and mapping of neural circuits. However, ChR2 variants selectively transported down a neuron’s long-range axonal projections for precise presynaptic activation remain lacking. As a result, ChR2 activation is often contaminated by the spurious activation of en passant fibers that compromise the accurate interpretation of functional effects. Here, we explored the engineering of a ChR2 variant specifically localized to presynaptic axon terminals. The metabotropic glutamate receptor 2 (mGluR2) C-terminal domain fused with a proteolytic motif and axon-targeting signal (mGluR2-PA tag) localized ChR2-YFP at axon terminals without disturbing normal transmission. mGluR2-PA-tagged ChR2 evoked transmitter release in distal projection areas enabling lower levels of photostimulation. Circuit connectivity mapping in vivo with the Spike Collision Test revealed that mGluR2-PA-tagged ChR2 is useful for identifying axonal projection with significant reduction in the polysynaptic excess noise. These results suggest that the mGluR2-PA tag helps actuate trafficking to the axon terminal, thereby providing abundant possibilities for optogenetic experiments. Nature Publishing Group UK 2021-04-12 /pmc/articles/PMC8042110/ /pubmed/33846537 http://dx.doi.org/10.1038/s42003-021-01977-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hamada, Shun
Nagase, Masashi
Yoshizawa, Tomohiko
Hagiwara, Akari
Isomura, Yoshikazu
Watabe, Ayako M.
Ohtsuka, Toshihisa
An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping
title An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping
title_full An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping
title_fullStr An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping
title_full_unstemmed An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping
title_short An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping
title_sort engineered channelrhodopsin optimized for axon terminal activation and circuit mapping
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042110/
https://www.ncbi.nlm.nih.gov/pubmed/33846537
http://dx.doi.org/10.1038/s42003-021-01977-7
work_keys_str_mv AT hamadashun anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT nagasemasashi anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT yoshizawatomohiko anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT hagiwaraakari anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT isomurayoshikazu anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT watabeayakom anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT ohtsukatoshihisa anengineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT hamadashun engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT nagasemasashi engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT yoshizawatomohiko engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT hagiwaraakari engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT isomurayoshikazu engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT watabeayakom engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping
AT ohtsukatoshihisa engineeredchannelrhodopsinoptimizedforaxonterminalactivationandcircuitmapping